NextPlat (NXPL) Income from Continuing Operations (2010 - 2026)
NextPlat's (NXPL) quarterly Income from Continuing Operations came in at -$144000.0 in Q2 2026, up 91.95% year-over-year from -$75019.2 in Q2 2025, and up 87.28% quarter-over-quarter from -$1.1 million in Q1 2026.
Powered by 
Analysis
NextPlat (NXPL) Income from Continuing Operations (2010 - 2026) Analysis & Trends
NextPlat (NXPL) has reported Income from Continuing Operations for 16 consecutive years, with -$144000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Income from Continuing Operations rose 91.95% year-over-year to -$144000.0 in Q2 2026; TTM through Jun 2026 was -$6.5 million, a 47.12% increase from a year earlier, with the FY2025 full-year figure at -$8.4 million, up 60.21% from the prior year.
- Income from Continuing Operations was -$144000.0 for Q2 2026 at NextPlat, up from -$1.1 million in the prior quarter.
- Over five years, Income from Continuing Operations peaked at -$144000.0 in Q2 2026 and troughed at -$12.0 million in Q4 2023.
- A 5-year average of -$3.1 million and a median of -$1.9 million in 2025 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations plunged 1955.04% in 2023 and surged 92.47% in 2024, its largest moves.
- Over 5 years, Income from Continuing Operations stood at -$586216.0 in 2022, then sank by 1955.04% to -$12.0 million in 2023, then surged by 92.47% to -$907000.0 in 2024, then slumped by 235.61% to -$3.0 million in 2025, then jumped by 95.27% to -$144000.0 in 2026.
- The last three Income from Continuing Operations figures came in at -$144000.0 (Q2 2026), -$1.1 million (Q1 2026), and -$3.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | -576.00 Mn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | -118.80 Mn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 45.93 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 69.61 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 260.00 Mn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 24.70 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | -66.70 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 30.35 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 1.97 Mn |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | -144,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -144,000.00 |
| Mar 31, 2026 | -1.13 Mn |
| Dec 31, 2025 | -3.04 Mn |
| Sep 30, 2025 | -2.19 Mn |
| Jun 30, 2025 | -1.79 Mn |
| Mar 31, 2025 | -1.94 Mn |
| Dec 31, 2024 | -907,000.00 |
| Sep 30, 2024 | -7.66 Mn |
| Jun 30, 2024 | -10.74 Mn |
| Mar 31, 2024 | -1.70 Mn |
| Dec 31, 2023 | -12.05 Mn |
| Sep 30, 2023 | -3.50 Mn |
| Jun 30, 2023 | -2.93 Mn |
| Mar 31, 2023 | -1.16 Mn |
| Dec 31, 2022 | -586,216.00 |
| Sep 30, 2022 | -2.26 Mn |
| Jun 30, 2022 | -1.66 Mn |
| Mar 31, 2022 | -832,902.00 |
| Dec 31, 2021 | -3.54 Mn |
| Sep 30, 2021 | -2.31 Mn |